Renovaro Biosciences Inc. (RENB)
USD 1.68
(1.2%)
USD 1.68
(1.2%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.97 Million | -11.77 Million | -15.73 Million | -20.61 Million | -10.45 Million | -8.5 Million |
| Net Income | -80.65 Million | -39.68 Million | -113.43 Million | -26.72 Million | -11.41 Million | -18.01 Million |
| Depreciation & Amortization | 121.85 Thousand | 113.49 Thousand | 123.59 Thousand | 123.53 Thousand | 366.26 Thousand | 71.7 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 4.67 Million | 3.53 Million | 5.49 Million | 1.44 Million | 1.02 Million | - |
| Change in working capital | 8.81 Million | 4.3 Million | 1.41 Million | 1.2 Million | -97.46 Thousand | 198.88 Thousand |
| Other non-cash items | 56.07 Million | 995.8 Thousand | -2.59 Million | 3.34 Million | -200.58 Thousand | 9.29 Million |
| Investing Cash Flow | -1.26 Million | -29.77 Thousand | -5156.00 | -48.89 Thousand | -184.46 Thousand | -716.66 Thousand |
| Investments in PPE | -70.43 Thousand | -29.77 Thousand | -5156.00 | -48.89 Thousand | -184.46 Thousand | -716.66 Thousand |
| Acquisitions | -1.18 Million | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1.25 Million | - | - | - | - | - |
| Financing Cash Flow | 10.51 Million | 4.51 Million | 4.25 Million | 32.6 Million | 7.2 Million | 6.02 Million |
| Debt repayment | -7.17 Million | -1.12 Million | -560.84 Thousand | -546.65 Thousand | -6.2 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3 Million | 4.01 Million | 4.67 Million | 33.06 Million | 1 Million | 6.02 Million |
| Other Financing Activities | 341.86 Thousand | 5636.82 | 4.67 Million | 1.22 Million | 1000.00 | - |
| Accounts receivables | -1.1 Million | 46.00 | 1594.00 | 342.00 | 18.81 Thousand | 119.83 Thousand |
| Accounts payables | 4.05 Million | 3.89 Million | 1.08 Million | -272.31 Thousand | 59.31 Thousand | -29.94 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5.86 Million | 410.15 Thousand | 332.2 Thousand | 1.2 Million | -175.59 Thousand | 109 Thousand |
| Cash at beginning of period | 1.87 Million | 9.17 Million | 20.66 Million | 8.69 Million | 12.28 Million | 15.6 Million |
| Cash at end of period | 220.46 Thousand | 1.87 Million | 9.17 Million | 20.66 Million | 8.69 Million | 12.28 Million |
| Capital Expenditure | -70.43 Thousand | -29.77 Thousand | -5156.00 | -48.89 Thousand | -184.46 Thousand | -716.66 Thousand |
| Effect of forex changes on cash | 60.14 Thousand | -8395.00 | -5240.00 | 26.11 Thousand | -141.97 Thousand | - |
| Net cash flow / Change in cash | -1.65 Million | -7.29 Million | -11.49 Million | 11.96 Million | -3.58 Million | -3.31 Million |
| Free Cash Flow | -11.04 Million | -11.8 Million | -15.73 Million | -20.65 Million | -10.64 Million | -9.22 Million |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -49.92 Million | -17.02 Million | -4.52 Million | -9.17 Million | -23.19 Million | -39.68 Million |
| Depreciation & Amortization | 31.13 Thousand | 30.3 Thousand | 33.16 Thousand | 27.26 Thousand | 28 Thousand | 113.49 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 828.47 Thousand | 1.86 Million | 999.22 Thousand | 983.82 Thousand | 612.88 Thousand | 3.53 Million |
| Change in working capital | 3.69 Million | 4.33 Million | 153.45 Thousand | 628.94 Thousand | 982.98 Thousand | 4.3 Million |
| Other non-cash items | 42.95 Million | -256.1 Thousand | 196.65 Thousand | 4.63 Million | 352.75 Thousand | 995.8 Thousand |
| Investing Cash Flow | -53.37 Thousand | -91.59 Thousand | -57.33 Thousand | -1.05 Million | -6141.00 | -29.77 Thousand |
| Investments in PPE | -23.55 Thousand | -5294.00 | -41.58 Thousand | - | -6141.00 | -29.77 Thousand |
| Acquisitions | -29.82 Thousand | 65.85 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -29.82 Thousand | -152.15 Thousand | -15.75 Thousand | -1.05 Million | - | - |
| Financing Cash Flow | 2.46 Million | 2.64 Million | 2.84 Million | 2.56 Million | 1.24 Million | 4.51 Million |
| Debt repayment | -1.82 Million | -2.28 Million | -2.5 Million | -562.81 Thousand | -280.77 Thousand | -1.12 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -1.34 Million | 1 Million | 341.86 Thousand | 2 Million | 1.52 Million | 4.01 Million |
| Other Financing Activities | 646.12 Thousand | 1536.06 | 2846.87 | 2562.82 | 1248.05 | 5636.82 |
| Accounts receivables | -1.1 Million | - | - | - | - | 46.00 |
| Accounts payables | 1.94 Million | 1.82 Million | 156.79 Thousand | 124.3 Thousand | 825.46 Thousand | 3.89 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.85 Million | -1651.00 | -1652.00 | 16.23 Thousand | 157.52 Thousand | 410.15 Thousand |
| Cash at beginning of period | 312.69 Thousand | 243.98 Thousand | 523.47 Thousand | 1.87 Million | 2.94 Million | 9.17 Million |
| Cash at end of period | 220.46 Thousand | 312.69 Thousand | 243.98 Thousand | 523.47 Thousand | 1.87 Million | 1.87 Million |
| Capital Expenditure | -23.55 Thousand | -5294.00 | -41.58 Thousand | - | -6141.00 | -29.77 Thousand |
| Effect of forex changes on cash | -91.79 Thousand | 153.07 Thousand | 77.59 Thousand | -78.74 Thousand | -53.85 Thousand | -8395.00 |
| Net cash flow / Change in cash | -92.23 Thousand | 68.71 Thousand | -279.49 Thousand | -1.35 Million | -1.07 Million | -7.29 Million |
| Free Cash Flow | -2.43 Million | -2.63 Million | -3.18 Million | -2.77 Million | -2.26 Million | -11.8 Million |
ACLLF
003690
EZPW
GBX
6743
MRF